Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Russo |
| Publié: |
IRBIS LLC
2019-01-01
|
| Collection: | Фармакоэкономика |
| Sujets: | |
| Accès en ligne: | https://www.pharmacoeconomics.ru/jour/article/view/268 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|